Advanced Scientific Review · 2025

GLP-1 Receptor
Agonists &
Neuroprotection

Cellular Mechanisms, Signaling Cascades & Clinical Frontiers

Glucagon-like peptide-1 receptor agonists have emerged as transformative agents beyond glycemic control, demonstrating profound neuroprotective activity across multiple CNS pathologies through intricate multi-modal cellular mechanisms.

~50%PD Risk Reduction
30+Active CNS Trials
7Approved Agents
BBBPenetrant Capacity
01 //

Biological Foundation

GLP-1 receptor expression in the CNS and the physiological basis of neuroprotective signaling

Glucagon-like peptide-1 (GLP-1) is an incretin hormone synthesized by intestinal L-cells and brainstem NTS neurons. In the periphery it potentiates glucose-stimulated insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. However, GLP-1 receptors (GLP-1R) are expressed broadly across the CNS — cortex, hippocampus, hypothalamus, basal ganglia, cerebellum, and brainstem — unveiling a neuroprotective biology that predates pharmaceutical exploitation.

GLP-1RAs bind GLP-1R with high affinity, activating neuroprotective cascades including cAMP/PKA, PI3K/Akt/mTOR, MAPK/ERK, and NF-kB suppression. Certain GLP-1RAs (exendin-4, liraglutide, semaglutide) exhibit sufficient properties to traverse the blood-brain barrier, achieving pharmacologically relevant CNS concentrations measurable in CSF and brain parenchyma. This positions them as compelling disease-modifying candidates for neurodegeneration.
02 //

Cellular Mechanisms of
Neuroprotection

Molecular detail of each protective pathway activated by GLP-1 receptor agonism in neuronal and glial cells

🧠

CNS GLP-1R Distribution

High-density expression in hippocampal CA1–CA3 and dentate gyrus, prefrontal cortex, substantia nigra pars compacta, striatum, hypothalamic nuclei, and cerebellar Purkinje cells. Receptor activation in these regions mediates memory consolidation, neuroprotection, and adult neurogenesis.

🔬

BBB Permeability

Semaglutide achieves CNS concentrations ~0.1% of plasma — sufficient for pharmacological effect given picomolar GLP-1R affinity. Liraglutide achieves measurable brain concentrations via circumventricular organ uptake and active transport. Intranasal formulations under development aim for direct olfactory-CNS delivery.

⚡

Neuronal vs. Glial Effects

GLP-1RAs exert effects on neurons (anti-apoptotic, BDNF induction, synaptic plasticity), astrocytes (glutamate uptake upregulation, anti-inflammatory cytokine modulation), and microglia (M1→M2 polarization, NLRP3 inflammasome suppression). Multi-cellular targeting confers broad neuroprotective coverage.

🔗

Metabolic-Neurological Axis

Insulin resistance, mitochondrial dysfunction, oxidative stress, and neuroinflammation are shared features of T2DM and neurodegeneration. GLP-1RAs address all four via overlapping mechanisms, explaining the disproportionate CNS benefit observed in both diabetic and non-diabetic populations.

02 //

Cellular Mechanisms of
Neuroprotection

Molecular detail of each protective pathway activated by GLP-1 receptor agonism in neuronal and glial cells

MECH·01

cAMP / PKA / CREB Axis — Transcriptional Survival Program

PRIMARY PATHWAY

Mechanistic Basis

GLP-1R is a Gs-protein coupled receptor. Upon agonist binding, Gαs dissociates and activates adenylyl cyclase, generating a rapid 5–10-fold surge in intracellular cAMP within minutes of GLP-1RA exposure in neurons.

Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP Response Element Binding Protein) at Ser133. Phospho-CREB recruits CBP/p300 co-activators to CRE promoter elements, driving expression of pro-survival genes including BDNF, BCL-2, BCL-XL, and MCL-1.

Simultaneously, PKA phosphorylates and inactivates BAD, preventing its interaction with anti-apoptotic BCL-2 family members. This dual action — transcriptional upregulation of survival proteins plus post-translational inactivation of pro-apoptotic proteins — establishes a robust anti-apoptotic checkpoint across hippocampal and dopaminergic neurons.

"Exendin-4 markedly increased CREB phosphorylation and BDNF expression in hippocampal neurons subjected to amyloid-β toxicity, reducing caspase-3 activation by over 70% — an effect fully abrogated by the PKA inhibitor H-89."

PERRY ET AL., J NEUROSCIENCE RESEARCH, 2002

cAMP also activates Epac1/2 (Exchange protein directly activated by cAMP) — an alternative effector promoting neurite outgrowth, synaptic vesicle priming, and Rap1-GEF pathway activation, enhancing neuronal plasticity independently of PKA.

Signal Cascade
→GLP-1RA binding → GLP-1R conformational change → Gαs dissociation
→Adenylyl cyclase activation → intracellular cAMP surge (5–10x baseline)
→PKA holoenzyme dissociation → catalytic subunit nuclear entry
→CREB phosphorylation (Ser133) → CBP/p300 co-activator recruitment
→CRE-driven transcription → ↑ BDNF, BCL-2, BCL-XL, c-FOS
→PKA phosphorylates BAD (Ser155) → 14-3-3 sequestration → anti-apoptosis
→Epac1/2 activation → Rap1-GEF → neurite outgrowth, synaptic plasticity
MECH·02

PI3K / Akt / mTOR — Insulin Sensitization & Protein Homeostasis

NEUROINSULIN AXIS

Central Insulin Resistance Reversal

Neurodegeneration is linked to brain insulin resistance — impaired IRS-1/PI3K/Akt signaling leading to tau hyperphosphorylation, amyloid production, and synaptic failure. GLP-1RAs restore this axis via both direct (GLP-1R→PI3K) and indirect (peripheral insulin sensitization) mechanisms.

GLP-1R couples to PI3K via Gβγ subunits and IRS-1 transactivation. Activated PI3K generates PIP3, recruiting Akt to the plasma membrane for PDK1-dependent phosphorylation at Thr308 and mTORC2-dependent phosphorylation at Ser473 — full Akt activation requiring both sites.

Activated Akt phosphorylates and inactivates GSK-3β (Ser9) — the principal kinase responsible for pathological tau phosphorylation at AT8 and PHF-1 epitopes — reducing neurofibrillary tangle formation. Akt activates mTORC1 through TSC1/2, stimulating autophagy flux via ULK1 and supporting protein quality control critical in proteotoxic diseases. Akt phosphorylates FOXO3a, excluding it from the nucleus and suppressing pro-apoptotic gene expression including BIM, FasL, and PUMA.

Signal Cascade
→GLP-1R → PI3Kγ (Gβγ) + IRS-1 transactivation at membrane
→PIP2 → PIP3 → PDK1/Akt membrane co-localization
→Akt (Thr308 + Ser473) → full kinase activation (dual phosphorylation)
→GSK-3β Ser9 phosphorylation → inhibition → ↓ tau hyperphosphorylation
→TSC1/2 phosphorylation → mTORC1 de-repression → autophagy flux ↑
→FOXO3a Ser253 phosphorylation → nuclear exclusion → ↓ BIM/PUMA/FasL
→mTORC2 → Akt Ser473 → completes pro-survival signaling feedback loop
MECH·03

Neuroinflammation Suppression — NF-κB, NLRP3 & Microglial Polarization

ANTI-INFLAMMATORY

Multi-Level Inflammatory Control

Chronic low-grade neuroinflammation driven by microglial activation, astrogliosis, and peripheral immune cell infiltration is a hallmark of virtually all neurodegenerative conditions. GLP-1RAs exert potent anti-inflammatory effects through several converging pathways.

NF-κB suppression: PKA-mediated phosphorylation of IκBα prevents its proteasomal degradation, trapping NF-κB (p65/p50) in the cytoplasm. The GLP-1RA/cAMP axis additionally upregulates IκBα transcription. The net effect is reduced nuclear NF-κB activity and attenuated expression of TNF-α, IL-1β, IL-6, COX-2, and iNOS in activated microglia and astrocytes.

NLRP3 inflammasome: GLP-1RAs suppress NLRP3 assembly — reducing ASC speck formation and caspase-1 cleavage — thereby preventing IL-1β and IL-18 maturation and pyroptotic neuronal death. This mechanism is particularly relevant in α-synuclein and Aβ-driven microglial activation in PD and AD.

Microglial M1→M2 polarization: GLP-1RA shifts microglia from pro-inflammatory M1 (↑ IL-1β, TNF-α, ROS, CD68) to neuroprotective M2 (↑ IL-10, TGF-β, arginase-1, CD206), promoting phagocytic clearance of protein aggregates without collateral neuronal damage.

Signal Cascade
→↑ cAMP → PKA → IκBα phosphorylation → protection from ubiquitin-proteasome degradation
→NF-κB cytoplasmic retention → ↓ TNF-α / IL-1β / IL-6 gene transcription
→NLRP3 priming signal suppression → ↓ NLRP3/ASC oligomerization
→↓ Pro-caspase-1 cleavage → ↓ mature IL-1β / IL-18 / pyroptosis
→Microglial M1→M2 shift → ↑ IL-10, arginase-1, phagocytic capacity
→Astrocyte EAAT2 upregulation → ↑ glutamate clearance → ↓ excitotoxicity
→↓ COX-2 / iNOS → ↓ prostaglandin E2 and peroxynitrite-mediated damage
MECH·04

Mitochondrial Biogenesis & Oxidative Stress Defence

METABOLIC PROTECTION

Mitochondrial Quality Control

Neurons are uniquely vulnerable to mitochondrial dysfunction given near-total dependence on oxidative phosphorylation. GLP-1RAs robustly stimulate PGC-1α — the master regulator of mitochondrial biogenesis — via CREB, AMPK, and SIRT1 activation.

↑ PGC-1α drives co-activation of NRF1/NRF2 and TFAM, enhancing transcription of mitochondrial respiratory chain complex subunits, improving ATP production efficiency, and reducing electron leak-driven superoxide generation at Complex I and Complex III.

GLP-1RAs activate Nrf2 through PKA-mediated phosphorylation, Akt-mediated Keap1 disruption, and direct ARE upregulation. This drives expression of HO-1, NQO1, GPx, catalase, thioredoxin, and superoxide dismutases, establishing a comprehensive antioxidant defence network.

Mitophagy regulation: GLP-1RAs modulate the PINK1/Parkin pathway, promoting selective autophagy of depolarized mitochondria. This prevents accumulation of damaged, ROS-generating organelles — critically relevant in PD where PINK1/Parkin mutations are causative of familial disease.

Signal Cascade
→CREB + AMPK activation → ↑ PGC-1α transcription + SIRT1-mediated deacetylation
→PGC-1α · NRF1 · TFAM complex → mitochondrial biogenesis (Complex I–V subunits)
→Keap1-Nrf2 dissociation → Nrf2 nuclear translocation → ARE binding
→↑ HO-1, NQO1, GPx1, SOD1/2, catalase → antioxidant enzyme induction
→↓ Mitochondrial membrane potential loss → ↓ cytochrome c release → ↓ apoptosis
→PINK1 stabilization on ΔΨm-low mitochondria → Parkin recruitment → ubiquitination → mitophagy
→↓ ROS, ↓ 4-HNE, ↓ protein carbonylation → preserved proteostasis network
MECH·05

Neurotrophic Support — BDNF, Neurogenesis & Synaptic Plasticity

REGENERATIVE

Neurotrophin Amplification

BDNF activates TrkB receptors to promote neuronal survival and synaptic strengthening via MAPK/ERK and PI3K/Akt. GLP-1RAs strongly upregulate BDNF via CREB in hippocampus, cortex, and striatum — liraglutide increases hippocampal BDNF by ~60–80% in rodent models, creating a self-reinforcing neuroprotective loop.

Hippocampal neurogenesis: The subgranular zone (SGZ) of the dentate gyrus harbors neural stem cells generating new granule neurons throughout adulthood. GLP-1RAs robustly stimulate SGZ neurogenesis — increasing BrdU+/NeuN+ cells, dendritic arborization, and LTP amplitude — through CREB, BDNF, and glucocorticoid signaling suppression.

Synaptic plasticity: GLP-1RAs enhance AMPA receptor surface expression (GluA1 Ser845 phosphorylation), increase PSD-95 and synapsin levels, and potentiate NMDA-dependent LTP. These effects correlate with improved spatial and recognition memory in AD and aging models. WNT/β-catenin: GSK-3β inhibition allows β-catenin nuclear translocation, amplifying neurogenic gene programs including NeuroD1, Prox1, and Ngn2.

Signal Cascade
→CREB phosphorylation → BDNF exon IV/VI transcription → mature BDNF secretion
→BDNF → TrkB autophosphorylation → PI3K/Akt + MAPK/ERK survival amplification loop
→SGZ neural stem cell activation → ↑ DCX+/PSA-NCAM+ neuroblasts → adult neurogenesis
→GSK-3β inhibition → β-catenin nuclear entry → WNT target gene activation
→GluA1 Ser845 phosphorylation → AMPAR exocytosis → synaptic potentiation (LTP ↑)
→↑ PSD-95, synapsin-I/II → dendritic spine density → memory consolidation
→Epac2 → Rap2 → TIAM1 → actin polymerization → spine morphogenesis
MECH·06

Anti-Apoptotic Control & ER Stress Resolution

CELL SURVIVAL

Intrinsic Apoptosis Suppression

Neuronal apoptosis in neurodegeneration proceeds primarily via the intrinsic (mitochondrial) pathway — triggered by DNA damage, ER stress, oxidative burden, and trophic factor withdrawal. GLP-1RAs intercept this pathway at multiple checkpoints.

BCL-2 family rebalancing: Via CREB-driven transcription, GLP-1RAs increase BCL-2 and BCL-XL and reduce BIM and PUMA. BCL-2 seals the mitochondrial outer membrane against BAX/BAK oligomerization, preventing cytochrome c release and apoptosome (Apaf-1/cytochrome c/pro-caspase-9) assembly.

ER stress (UPR) resolution: Accumulation of misfolded proteins activates the UPR through IRE1α, PERK, and ATF6 sensors. Chronic UPR activation drives CHOP-mediated apoptosis. GLP-1RAs upregulate ER chaperones (GRP78, GRP94) via ATF6, activate the adaptive IRE1α-XBP1s arm, and suppress terminal CHOP — resolving proteotoxic ER stress. Caspase inhibition is further achieved through Akt phosphorylation of pro-caspase-9 (Ser196) and increased XIAP expression directly inhibiting effector caspases-3 and -7.

Signal Cascade
→↑ BCL-2 / BCL-XL → BAX/BAK conformational neutralization → outer mitochondrial membrane integrity
→↓ Cytochrome c release → ↓ Apaf-1 apoptosome assembly → ↓ caspase-9 activation
→↑ GRP78 / GRP94 (BiP) → ER chaperone buffering → ↓ misfolded protein accumulation
→IRE1α → XBP1s (adaptive arm) → ↑ ERAD pathway → ↓ protein aggregate load
→↓ PERK/eIF2α/ATF4/CHOP axis → ↓ BIM transcription → ↓ ER stress apoptosis
→Akt → pro-caspase-9 (Ser196) → inhibition of activation complex
→↑ XIAP / Survivin → direct caspase-3/7 inhibition at IAP binding groove
03 //

Integrated Signaling
Architecture

Cross-pathway interactions and convergence points in GLP-1RA neuroprotection

GLP-1RA Neuroprotective Signaling Network

INTRACELLULAR · MULTI-PATHWAY · CROSS-REGULATORY

PLASMA MEMBRANE GLP-1RA AGONIST GLP-1 Receptor Gs-GPCR Adenylyl Cyclase ↑ cAMP (5–10×) PKA Activation Ser/Thr Kinase CREB (pSer133) Transcription Factor ↑ BDNF / BCL-2 Neurotrophin / Survival PI3K → PIP3 Lipid Signaling Akt (T308 + S473) Survival Kinase ↓ GSK-3β / ↑ mTOR Tau / Autophagy ↓ Tau-P / Proteostasis Protein Homeostasis ↓ NF-κB / NLRP3 Inflammatory Block ↑ Nrf2 / PGC-1α Redox Sensors M2 Microglia / ↑ HO-1 Anti-inflammatory ↓ ROS / ↓ Cytokines Oxidative Defence crosstalk crosstalk cAMP/PKA/CREB PI3K/Akt/mTOR Inflammation/Redox Neuroprotective Output
04 //

Disease-Specific
Neuroprotection

Mechanistic evidence and clinical data across major CNS pathologies

NEURODEGENERATIVE
Alzheimer's Disease
Evidence StrengthSTRONG
  • GSK-3β inhibition reduces tau phosphorylation at Ser396/Thr231 (PHF-1 epitope) by 40–70% in 3xTg-AD mice
  • Liraglutide and semaglutide reduce amyloid-β plaque burden in APP/PS1 models by 25–50% via ADAM10 upregulation and IDE (insulin-degrading enzyme) enhancement
  • Restoration of hippocampal IRS-1/Akt rescues synaptic LTP and spatial memory in AD models
  • CREB-driven BDNF upregulation reverses cholinergic neuron loss in basal forebrain
  • ↓ amyloid-triggered microglial M1 activation; ↓ BACE1 expression reduces Aβ production
  • ELAD trial (liraglutide): slowed FDG-PET hypometabolism progression and cognitive decline (Phase II)
  • EVOKE Phase III (semaglutide): 1,840 patients, CDR-SB primary endpoint — results 2025–26
SYNUCLEINOPATHY
Parkinson's Disease
Evidence StrengthVERY STRONG
  • Exenatide Phase II RCT (Athauda 2017): ~12-point sustained MDS-UPDRS improvement vs placebo at 60 weeks post-washout — suggesting genuine disease modification
  • GLP-1RAs protect dopaminergic neurons in MPTP, 6-OHDA, rotenone, and α-synuclein overexpression models
  • PINK1/Parkin mitophagy enhancement selectively clears damaged mitochondria in substantia nigra
  • ↓ α-synuclein aggregation via UPS and autophagy upregulation; ↓ Lewy body formation in cell models
  • Large Danish cohort: semaglutide associated with ~48% reduced PD incidence (Holst et al., 2024)
  • SPARK trial (semaglutide, Phase II, DaT-SPECT primary) actively recruiting
MOTOR NEURON
ALS / Motor Neuron Disease
Evidence StrengthMODERATE
  • GLP-1R expressed on spinal motor neurons and astrocytes in human ALS post-mortem tissue
  • Exendin-4 delays motor neuron death and extends survival in SOD1-G93A mouse model
  • ↓ TDP-43 cytoplasmic mislocalization via autophagy enhancement (ULK1/Beclin-1)
  • Anti-excitotoxic: ↑ astrocytic EAAT2 reduces motor neuron glutamate burden significantly
  • ↓ Neuroinflammatory progression: ↓ microglial-mediated motor cortex damage in preclinical models
  • First dedicated Phase II trial (semaglutide; ALSFRS-R primary, NfL secondary) underway
ACUTE INJURY
Stroke & Traumatic Brain Injury
Evidence StrengthSTRONG
  • GLP-1RA preconditioning reduces infarct volume by 30–50% in transient and permanent MCAO models
  • ↓ NMDA-mediated Ca²⁺ overload via PKA-dependent NR2B-containing NMDA receptor modulation
  • PKA/CREB activation within 2h of ischemia maintains penumbra neuronal viability
  • BBB protection: ↓ MMP-9 activity, ↑ occludin/claudin-5 tight junction expression → ↓ vasogenic edema
  • TBI: ↓ neuroinflammatory secondary injury, ↓ axonal TAI (traumatic axonal injury) extent
  • Post-hoc cardiovascular trial data (LEADER, SUSTAIN) show stroke risk reduction — CNS trials ongoing
NEUROPSYCHIATRIC
Depression & Cognitive Decline
Evidence StrengthEMERGING–STRONG
  • GLP-1RA treatment in T2DM significantly reduces PHQ-9 depression scores beyond glycemic benefit
  • ↑ Hippocampal neurogenesis (BrdU+/NeuN+) in chronic stress models — mechanistic basis for antidepressant effect
  • HPA axis normalization via direct hypothalamic GLP-1R activation → ↓ glucocorticoid neurotoxicity
  • ↑ Prefrontal BDNF and synaptic plasticity correlate with cognitive improvement in diabetic rodents
  • TriNetX analysis: ~40% reduction in new depression diagnoses in semaglutide users vs. controls (2M+ patients)
  • Epidemiological signals for addiction behaviour and anxiety reduction under active investigation
DEMYELINATING
MS & Optic Neuritis
Evidence StrengthMODERATE–EMERGING
  • GLP-1R expressed on oligodendrocytes and OPCs; agonism promotes differentiation and remyelination
  • Liraglutide reduces EAE severity by suppressing Th17 differentiation and CNS T-cell infiltration
  • ↑ Myelin basic protein (MBP) and MAG expression; ↓ demyelination in cuprizone model
  • Optic neuritis Phase II pilot: GLP-1RA protects RNFL thickness and visual acuity vs. placebo (positive)
  • ↓ CNS macrophage/microglia activation reduces axonal transection at spinal cord lesion margins
  • GLARE confirmatory trial (exenatide, OCT primary) actively enrolling
05 //

Clinical Trial Landscape

Key completed, ongoing and planned trials evaluating GLP-1RA neuroprotection in humans

EXENATIDE-PD
NCT01174810
Exenatide for Parkinson's Disease — Phase II RCT (Athauda 2017)
60 patients with moderate PD. Subcutaneous exenatide 2mg weekly vs placebo × 48 weeks + 12-week washout. Result: +12-point sustained MDS-UPDRS motor improvement vs placebo at 60-week washout assessment, suggesting genuine disease modification. CSF biomarkers demonstrated improved insulin signaling (pAkt/Akt ratio). Landmark proof-of-concept for GLP-1RA as a neuroprotective agent in humans.
Completed
EXENATIDE-PD3
NCT04232969
Exenatide Once-Weekly PD — Phase III (2024)
200 patients, multicentre UK trial. 96-week treatment + 24-week washout. Primary: MDS-UPDRS Parts II+III off-medication. Result: No significant difference in primary endpoint. However, post-hoc analyses indicate subgroup benefit in de novo, early-stage PD patients. Ongoing debate regarding patient selection, disease stage stratification, and whether dose was adequate for full CNS effect.
Completed
SPARK
NCT05788016
Semaglutide in Parkinson's Disease — Phase II
High-dose oral semaglutide (14mg) vs placebo in 120 early PD patients × 52 weeks. Primary: dopaminergic pathway integrity by DaT-SPECT. Secondary: MDS-UPDRS, cognitive measures, neuroinflammatory biomarkers. Strongly motivated by large-scale epidemiological data showing ~48% PD risk reduction in semaglutide users. Expected completion 2026.
Active
ELAD
NCT01843075
Evaluation of Liraglutide in Alzheimer's Disease — Phase II
206 early AD patients, 26-week liraglutide vs placebo. Primary: cerebral glucose metabolism (FDG-PET). Result: Significant attenuation of frontotemporal hypometabolism progression. Trend toward cognitive preservation and favourable CSF p-tau/Aβ42 direction. Led directly to the EVOKE Phase III programme with semaglutide.
Completed
EVOKE / EVOKE+
NCT04777396
Semaglutide in Early Alzheimer's Disease — Phase III
Twin Phase III trials, 1,840 patients total with MCI or early AD. Oral semaglutide 14mg vs placebo × 156 weeks. Primary: CDR-SB. Biomarker substudy: CSF p-tau181, amyloid-PET, tau-PET. Results expected 2025–2026. Industry-independent academic funding. Potentially the most significant AD disease-modification trial since lecanemab.
Active
REMODEL
NCT05475470
Liraglutide for Vascular Cognitive Impairment
240 patients with white matter hyperintensity-associated cognitive decline. Liraglutide 1.8mg vs placebo × 78 weeks. Primary: MoCA and Trails B. Imaging: ASL-MRI cerebral blood flow, white matter volume. Rationale includes endothelial GLP-1R activation, ↓ neuroinflammation, and blood pressure lowering as complementary cerebrovascular-protective mechanisms.
Recruiting
GLARE
NCT05540756
GLP-1RA for Retinal Neuroprotection in Optic Neuritis
80 patients with first acute optic neuritis. Exenatide LAR 2mg weekly × 24 weeks. Primary: RNFL thickness by OCT at 6 months. Secondary: visual acuity, contrast sensitivity, VEP latency. Preceded by a positive Phase II pilot trial showing GLP-1RA-mediated preservation of retinal ganglion cells — a tractable model for broader CNS neuroprotection assessment.
Active
GLP-1-ALS
NCT05563597
Semaglutide in ALS — Phase II Pilot
60 ALS patients stratified by progression rate. Semaglutide 2.4mg weekly vs placebo × 48 weeks. Primary: ALSFRS-R slope. Secondary: CSF cytokines (IL-6, IL-18, CXCL10), NfL, SOD1 levels. First prospective randomised trial of GLP-1RA in motor neuron disease. Preclinical rationale from SOD1-G93A models showing significant motor neuron preservation and lifespan extension.
Phase II
06 //

GLP-1RA Agents —
Neuroprotective Profiles

Comparative pharmacology of approved and investigational agents relevant to CNS neuroprotection

Exenatide
Exendin-4 · Byetta / Bydureon
OriginHeloderma venom peptide
GLP-1R Affinity~1 nM
Half-life2.4h / 7d (LAR)
BBB PenetrationModerate (CVO pathway)
CNS EvidencePD, stroke, TBI, AD
Key TrialExenatide-PD Phase II (+)
Liraglutide
Victoza / Saxenda
OriginAcylated GLP-1 analogue
GLP-1R Affinity~0.7 nM
Half-life~13 hours
BBB PenetrationGood — measurable brain conc.
CNS EvidenceAD, PD, VCI, optic neuritis
Key TrialELAD (FDG-PET positive)
Semaglutide
Ozempic / Wegovy / Rybelsus
OriginC18 diacid GLP-1 analogue
GLP-1R Affinity~0.4 nM (highest)
Half-life~7 days
BBB Penetration~0.1% plasma (measurable)
CNS EvidenceAD, PD, depression, cognition
Key TrialEVOKE Phase III (ongoing)
Dulaglutide
Trulicity
OriginGLP-1/IgG4-Fc fusion
GLP-1R Affinity~0.9 nM
Half-life~5 days
BBB PenetrationLow (large molecular weight)
CNS EvidenceCognitive benefit (REWIND post-hoc)
NoteREWIND: ↓ cognitive decline confirmed
NLY01
PEGylated Exendin-4 · Neuraly
OriginLong-acting PEGylated exendin-4
GLP-1R AffinitySub-nM
Half-life~7 days (PEG-extended)
BBB PenetrationBrain-enriched design target
CNS DesignPD-specific CNS optimised
Key TrialPhase II PD ongoing (Neuraly)
Tirzepatide
Mounjaro / Zepbound · GLP-1/GIP dual
MechanismDual GLP-1R + GIPR agonism
GLP-1R Affinity~0.5 nM
Half-life~5 days
BBB AdvantageGIPR on hippocampal neurons adds CNS axis
CNS InterestEmerging preclinical AD data
StatusNo dedicated CNS trials yet
07 //

Emerging Frontiers &
Research Priorities

Critical knowledge gaps and mechanistic insights shaping the next decade

🔭

Brain-Penetrant Next-Gen GLP-1RAs

Second-generation CNS-optimised agents (NLY01, intranasal liraglutide, oral semaglutide CNS formulations) target enhanced BBB penetrance. The critical question is whether superior CNS concentrations translate to meaningfully greater neuroprotection, or whether peripheral metabolic effects via the gut-brain axis are the primary driver of observed clinical benefit.

🧬

Gut-Brain Axis & Vagal Circuitry

Enteroendocrine L-cells and nodose ganglion vagal afferents provide a peripheral GLP-1 signal to brainstem NTS neurons projecting throughout the limbic system. This gut-brain circuit may be as neuroprotective as direct CNS GLP-1R activation, raising the possibility that vagus nerve integrity is required for the full therapeutic benefit of peripheral GLP-1RA administration.

⚙️

Biased Agonism for Neuroprotection

GLP-1R signals through Gs, Gq, G12/13, and β-arrestin pathways. Evidence suggests Gs-biased agonists (maximal cAMP) provide superior neuroprotection with reduced GI adverse effects. Rational design of β-arrestin-biased vs. Gs-biased GLP-1RAs could yield CNS-optimised molecules with substantially improved tolerability, enabling higher CNS-effective dosing.

🎯

Patient Stratification Biomarkers

Not all patients respond equally. Emerging evidence suggests GLP-1RA neuroprotection is greatest in those with metabolic co-morbidity, high inflammatory burden (elevated CRP, IL-6, neurofilament light chain), or specific genetic backgrounds (APOE ε4 in AD; GBA mutations in PD). Predictive biomarkers are critical for precision trial design and regulatory approval.

💊

Rational Combination Neurotherapeutics

GLP-1RAs synergise mechanistically with SGLT-2 inhibitors (additive mitochondrial and anti-inflammatory effects), amyloid-targeting antibodies (complementary mechanisms — metabolic vs. immunological clearance), and levodopa/dopamine agonists in PD. Phase II combination trials are warranted to evaluate synergistic disease-modifying efficacy beyond single-agent effects.

🔬

Sex, Age & GLP-1R Expression Modifiers

Preclinical studies show sex differences in GLP-1RA neuroprotection: female animals exhibit greater BDNF upregulation and hippocampal neurogenic responses. Age-related GLP-1R downregulation in the ageing brain may limit efficacy in older populations. Sex-stratified analyses and dose-escalation strategies in elderly patients warrant systematic prospective investigation.

"The convergence of robust epidemiological signals from tens of millions of diabetic patients, mechanistic precision from cellular and animal models, and emerging positive clinical trial data positions GLP-1 receptor agonists as the most promising class of disease-modifying neurotherapeutics currently in human investigation — a therapeutic repurposing of extraordinary scope and translational velocity."

SYNTHESISED FROM: ATHAUDA & FOLTYNIE, LANCET NEUROLOGY 2016 · HOLSCHER, CNS DRUGS 2020 · NOYCE ET AL., MOVEMENT DISORDERS 2023 · MEFTAH & CAI, NATURE REVIEWS NEUROLOGY 2024
REF //

Key References

Primary and review literature supporting the mechanisms and clinical evidence described throughout

1Athauda D, Maclagan K, Skene SS et al. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 390(10103):1664–1675.
2Athauda D, Gulyani S, Karnati HK et al. (2019). Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurology 76(4):420–429.
3Perry T, Lahiri DK, Sambamurti K et al. (2002). Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide levels and protects hippocampal neurons from death induced by Abeta and iron. Journal of Neuroscience Research 72(5):603–612.
4McClean PL, Parthsarathy V, Faivre E, Hölscher C. (2011). The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. Journal of Neuroscience 31(17):6587–6594.
5Femminella GD, Frangou E, Love SB et al. (2019). Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD trial). Trials 20(1):191.
6Hölscher C. (2020). Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opinion on Investigational Drugs 29(4):333–348.
7Aviles-Olmos I, Dickson J, Kefalopoulou Z et al. (2013). Exenatide and the treatment of patients with Parkinson's disease. Journal of Clinical Investigation 123(6):2730–2736.
8Liu W, Jalewa J, Sharma M, Li G, Li L, Hölscher C. (2015). Neuroprotective effects of liraglutide in the MPTP mouse model of Parkinson's disease. Neuroscience 303:42–50.
9Teramoto S, Miyamoto N, Yatomi K et al. (2011). Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism 31(8):1696–1705.
10Cai HY, Wang ZJ, McCarthy J et al. (2019). Liraglutide rescues hippocampal neurons from Abeta-induced apoptosis by promoting autophagy via GLP-1R/PI3K/Akt/mTOR pathway. Neuropharmacology 151:39–51.
11Harkavyi A, Abuirmeileh A, Lever R et al. (2008). Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation 5:19.
12Jalewa J, Sharma MK, Gengler S, Hölscher C. (2017). A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. Neuropharmacology 117:238–248.
13Holst JJ, Burcelin R, Nathanson E. (2011). Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research and Opinion 27(3):547–558.
14Meftah S, Cai J. (2024). Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression. Nature Reviews Neurology 20:282–300.
15Noyce AJ, Bestwick JP, Silveira-Moriyama L et al. (2023). GLP-1 receptor agonists and Parkinson's disease: a systematic review and meta-analysis. Movement Disorders 38(9):1712–1723.